Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

161. Multiple Sclerosis and Management of Urinary Tract Infection

Multiple Sclerosis and Management of Urinary Tract Infection MULTIPLE SCLEROSIS AND MANAGEMENT OF URINARY TRACT INFECTION Clinical Practice Guideline | November 2013 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. GOALS Urgent primary care assessment and management of urinary tract infections (UTIs (...) ) in patients with multiple sclerosis (MS) Preventing re-occurrence of UTIs TARGET POPULATION Adults with multiple sclerosis (MS) displaying signs and symptoms (typical and atypical) suggesting urinary tract infection (UTI) Adults with MS living in the community; ambulatory care setting EXCLUSIONS Institutionalized patients, i.e., nursing homes, long term care RECOMMENDATIONS ASSESSMENT X Do not wait to assess. ? Same day attention in primary care is strongly recommended. ? Assess for indicators of urinary

Toward Optimized Practice2014

162. Multiple sclerosis in adults: management

Multiple sclerosis in adults: management Multiple sclerosis in adults: management Multiple sclerosis in adults: management Clinical guideline Published: 8 October 2014 nice.org.uk/guidance/cg186 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Multiple sclerosis in adults: management (CG186) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents Overview 4 Who is it for? 4

National Institute for Health and Clinical Excellence - Clinical Guidelines2014

163. Effects of Reduced-fat Diet in Combination with Omega-3 Fatty Acid Supplementation on Exacerbations of Multiple Sclerosis

Effects of Reduced-fat Diet in Combination with Omega-3 Fatty Acid Supplementation on Exacerbations of Multiple Sclerosis "Effects of Reduced-fat Diet in Combination with Omega-3 Fatty Acid Sup" by Brooke A. Barnes < > > > > > Off-campus Pacific University users: To download campus access theses and dissertations, please with your PUNet ID and password. Non-Pacific University users: Please talk to your librarian about requesting this thesis or dissertation through interlibrary loan. Theses (...) or dissertations that have a specific embargo period indicated below will not be available to anyone until the date indicated. Title Author Date of Award Summer 8-9-2014 Degree Type Capstone Project (On-Campus Access Only) Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Multiple sclerosis (MS) is a chronic disabling disease which affects over 2.5 million people in the world and approximately 500 000 people in the United States. MS is an inflammatory demyelinating

Pacific University EBM Capstone Project2014

164. Complementary and alternative medicine in multiple sclerosis

Complementary and alternative medicine in multiple sclerosis Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share March 25, 2014 ; 82 (12) Special Article Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis Report of the Guideline (...) , Portland; MS Center of Excellence–East (C.B.), VA Maryland Health Care System and Department of Neurology (C.B.), University of Maryland School of Medicine, Baltimore; Multiple Sclerosis Center (J.B.), Swedish Neuroscience Institute, Seattle, WA; Multiple Sclerosis Service and Complementary and Alternative Medicine Service (A.B.), Colorado Neurological Institute, Englewood; The Jacobs Neurological Institute (B.W.-G.), Buffalo, NY; Department of Neurology (G.S.G.), University of Kansas Medical Center

American Academy of Neurology2014

165. Assessment and management of psychiatric disorders in individuals with multiple sclerosis

Assessment and management of psychiatric disorders in individuals with multiple sclerosis Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share January 14, 2014 ; 82 (2) Special Article Evidence-based guideline: Assessment and management of psychiatric disorders (...) in individuals with MS Report of the Guideline Development Subcommittee of the American Academy of Neurology Sarah L. Minden , Anthony Feinstein , Rosalind C. Kalb , Deborah Miller , David C. Mohr , Scott B. Patten , Christopher Bever , Randolph B. Schiffer , Gary S. Gronseth and Pushpa Narayanaswami First published December 27, 2013, DOI: https://doi.org/10.1212/WNL.0000000000000013 Sarah L. Minden From the Department of Psychiatry, Brigham and Women's Hospital (S.L.M.), and Department of Neurology, Beth

American Academy of Neurology2014

166. Clinical review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis

Clinical review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Clinical Review Report; SR0350. 2014 Authors' conclusions Based on the results of two phase 3 double-blind randomized controlled trials, teriflunomide 14 mg may reduce the annualized relapse rate (ARR) by approximately 30% to 35% compared

Health Technology Assessment (HTA) Database.2014

167. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis

Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH (...) . Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0350. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that teriflunomide not be listed at the submitted price. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Administration, Oral; Canada; Crotonates; Drug Evaluation; Immunologic Factors; Multiple Sclerosis

Health Technology Assessment (HTA) Database.2014

168. Pharmacoeconomic review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis

Pharmacoeconomic review report. Teriflunomide (Aubagio ? Genzyme Canada) indication: relapsing-remitting multiple sclerosis Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic Review Report; SR0350. 2014 Authors' conclusions CDR found several limitations with the manufacturer's economic analysis. A reanalysis addressing all of these limitations (except treatment waning

Health Technology Assessment (HTA) Database.2014

169. Daclizumab for relapsing remitting multiple sclerosis.

Daclizumab for relapsing remitting multiple sclerosis. BACKGROUND: Monoclonal antibodies such as daclizumab could be a possible alternative immunotherapy to interferon beta treatment in people with multiple sclerosis (MS). It blocks the interleukin-2 receptor alpha subunit (CD25), and seems to be beneficial to patients with relapsing remitting multiple sclerosis (RRMS) in clinical and magnetic resonance imaging (MRI) measures of outcomes.This is an update of a Cochrane review first published (...) in 2010, and previously updated in 2012. OBJECTIVES: To assess the safety of daclizumab and its efficacy to prevent clinical worsening in patients with RRMS. SEARCH METHODS: The Trials Search Co-ordinator searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (17 May 2013). We handsearched the references quoted in the identified trials and reports (May 2013) from the most important neurological associations and MS societies. We contacted

Cochrane2013

170. Pharmacological treatment for memory disorder in multiple sclerosis.

Pharmacological treatment for memory disorder in multiple sclerosis. BACKGROUND: This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10).Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system (CNS) and can cause both neurological and neuropsychological disability. Both demyelination and axonal (...) and neuronal loss are believed to contribute to MS-related cognitive impairment. Memory disorder is one of the most frequent cognitive dysfunctions and presents a considerable burden to people with MS and to society due to the negative impact on function. A number of pharmacological agents have been evaluated in many existing randomised controlled trials for their efficacy on memory disorder in people with MS but the results were not consistent. OBJECTIVES: To assess the absolute and comparative efficacy

Cochrane2013

171. Rituximab for relapsing-remitting multiple sclerosis.

Rituximab for relapsing-remitting multiple sclerosis. BACKGROUND: This is an update of the Cochrane review "Rituximab for relapsing-remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately 10 years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RRMS) convert to secondary progressive MS. MS causes a major (...) socioeconomic burden for the individual patient and for society. Effective treatment that reduces relapse frequency and prevents progression could impact both costs and quality of life and help to reduce the socioeconomic burden of MS. Alternative and more effective MS treatments with new modes of action and good safety are needed to expand the current treatment repertoire. It has been shown that B lymphocytes are involved in the pathophysiology of MS and rituximab lyses B-cells via complement-dependent

Cochrane2013

172. A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis

A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis Pozuelo-Moyano B, Benito-Leon J, Mitchell AJ, Hernandez-Gallego J CRD (...) summary The authors' cautious conclusion that there was a lack of evidence to support vitamin D as a treatment for multiple sclerosis, can be considered to be reliable. Authors' objectives To review the evidence for vitamin D in the treatment of multiple sclerosis. Searching PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to August 2012. Keywords were reported. Personal files, reference lists, and reviews of vitamin D supplementation were searched. No language

DARE.2013

173. Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study.

Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. BACKGROUND: Chronic cerebrospinal venous insufficiency has been proposed as a unique combination of extracranial venous blockages and haemodynamic flow abnormalities that occurs only in patients with multiple sclerosis and not in healthy people. Initial reports indicated that all patients with multiple sclerosis had (...) chronic cerebrospinal venous insufficiency. We aimed to establish the prevalence of venous narrowing in people with multiple sclerosis, unaffected full siblings, and unrelated healthy volunteers. METHODS: We did an assessor-blinded, case-control, multicentre study of people with multiple sclerosis, unaffected siblings, and unrelated healthy volunteers. We enrolled the study participants between January, 2011 and March, 2012, and they comprised 177 adults: 79 with multiple sclerosis, 55 siblings

Lancet2013

174. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.

Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Multiple sclerosis is a major cause of neurological disability, and particularly occurs in young adults. It is characterised by conspicuous patches of damage throughout the brain and spinal cord, with loss of myelin and myelinating cells (oligodendrocytes), and damage to neurons and axons. Multiple sclerosis is incurable, but stem-cell therapy might offer valuable therapeutic (...) potential. Efforts to develop stem-cell therapies for multiple sclerosis have been conventionally built on the principle of direct implantation of cells to replace oligodendrocytes, and therefore to regenerate myelin. Recent progress in understanding of disease processes in multiple sclerosis include observations that spontaneous myelin repair is far more widespread and successful than was previously believed, that loss of axons and neurons is more closely associated with progressive disability than

Lancet2013

176. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis A pragmatic parallel arm multi-centre randomised controlled trial to assess (...) the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis Thomas S, Thomas PW, Kersten P, Jones R, Green C, Nock A, Slingsby V, Smith AD, Baker R, Galvin KT, Hillier C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study

NHS Economic Evaluation Database.2013

177. Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial

Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial Humphreys I, Drummond AE, Phillips C, Lincoln NB Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the cost-effectiveness of psychological adjustment group therapy for multiple sclerosis patients with low mood. The authors concluded that the group therapy was a cost-effective intervention in the short term. Although the study methods appeared reasonable on the whole, the results

NHS Economic Evaluation Database.2013

178. [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis]

[Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Eficacia y seguridad de los fármacos inmunoreguladores, interferón beta y glatiramero, en la esclerosis múltiple remitente recidivante [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Eficacia y seguridad de los fármacos inmunoreguladores, interferón beta y (...) glatiramero, en la esclerosis múltiple remitente recidivante [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Martínez Férez IM, Flores Moreno S, Rodríguez López R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Martínez Férez IM, Flores Moreno S, Rodríguez

Health Technology Assessment (HTA) Database.2013

179. Botulinum toxin type a (Botox) - Management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis

Botulinum toxin type a (Botox) - Management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis

Scottish Medicines Consortium2013

180. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis 23695501 2013 09 04 2013 11 08 2017 02 20 1468-330X 84 10 2013 Oct Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatr. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue (...) management programme (FACETS) for people with multiple sclerosis. 1092-9 10.1136/jnnp-2012-303816 Fatigue is a common and troubling symptom for people with multiple sclerosis (MS). To evaluate the effectiveness and cost-effectiveness of a six-session group-based programme for managing MS-fatigue (Fatigue: Applying Cognitive behavioural and Energy effectiveness Techniques to lifeStyle (FACETS)). Three-centre parallel arm randomised controlled trial with economic evaluation. Patients with MS and

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro